134069-68-4
134069-68-4 結(jié)構(gòu)式
基本信息
中文別名
化合物 T13107 英文別名
TDN 3451-Oxa-3,8-diazaspiro[4.5]decan-2-one, 8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-
物理化學(xué)性質(zhì)
沸點(diǎn)556.2±60.0 °C(Predicted)
密度1.18±0.1 g/cm3(Predicted)
儲(chǔ)存條件-20°C儲(chǔ)存
溶解度溶于二甲基亞砜
酸度系數(shù)(pKa)9.67±0.20(Predicted)
常見問題列表
生物活性
TDN345 A 是一種 Ca2+ 拮抗劑，主要用于血管和老年癡呆疾病，例如阿爾茨海默癥的研究。體外研究
TDN-345 (10 μM) significantly increases the intracellular NGF content in the time-course study. TDN-345 induces NGF synthesis/secretion at the concentrations of 0.1 μM; statistically significant at 1 μM. The ED 50 is 0.88 μM.
體內(nèi)研究
TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score when administered orally twice, 60 min before ischemia and 90 min after recirculation. Additionally, TDN-345 (0.2 or 1.0 mg/kg, p.o. once daily for 3 weeks after the onset of stroke) decreases the mortality and recurrence of stroke in SHRSP.